geometrybase
8a0dfd88f0
Request: - Add extracted PDF text generation to the archivist workflow as a standard step. Changes: - Run PDF text extraction automatically for newly archived HKEX PDF sources. - Make the PDF text extractor incremental and manifest-preserving. - Document extracted-text handling in the archivist skill and README. - Mark generated extracted text as no-diff data evidence. - Backfill extracted text for all archived PDF source references. Verification: - Ran git diff --cached --check. - Ran .venv/bin/python -m py_compile scripts/extract_pdf_text.py scripts/archive_hkex_documents.py. - Ran full PDF extraction, then confirmed an incremental rerun skips unchanged files. - Verified 557 PDF source_refs, 557 manifest rows, all status ok, and zero missing text/hash/path issues. Next useful context: - HKEX HTML notices and Yahoo JSON market data remain under data/raw and are not expected in data/extracted_text.
1561 lines
60 KiB
Plaintext
1561 lines
60 KiB
Plaintext
--- page 1 ---
|
||
1
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
|
||
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
|
||
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
|
||
announcement.
|
||
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
|
||
defined in the Hong Kong prospectus dated December 30, 2025 (the “Prospectus ”) of Shenzhen Edge Medical Co.,
|
||
Ltd. (ʮ̡ ) (the “Company ”).
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
|
||
or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus
|
||
for detailed information about the Global Offering described below before deciding whether or not to invest in
|
||
the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the
|
||
information provided in the Prospectus.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
|
||
(including its territories and possessions, any state of the United States and the District of Columbia). This
|
||
announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities
|
||
in the United States or in any other jurisdictions. The Offer Shares have not been and will not be registered under
|
||
the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act ”) or securities law
|
||
of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred
|
||
within the United States, except in transactions exempt from, or not subject to, the registration requirements of the
|
||
U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the
|
||
Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional
|
||
buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S.
|
||
Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S.
|
||
Securities Act and applicable laws of each jurisdiction where those offers and sales occur.
|
||
In connection with the Global Offering, Morgan Stanley Asia Limited as stabilizing manager (the “Stabilization
|
||
Manager ”) (or its affiliates or any person acting for it), on behalf of the Underwriters, the extent permitted by the
|
||
applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions
|
||
with a view to stabilizing or supporting the market price of the H Shares at such price, in such amounts and in such
|
||
manners as the Stabilization Manager, its affiliates or any person acting for it may determine and at a level higher
|
||
than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation
|
||
on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action.
|
||
Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its
|
||
affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest
|
||
of our Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of
|
||
the last day for lodging applications under the Hong Kong Public Offering. Such Stabilizing action, if taken, may be
|
||
effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules
|
||
and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws
|
||
of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong
|
||
Kong). Potential investors should be aware that no stabilizing action can be taken to support the price of the H Shares
|
||
for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on the 30th
|
||
day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further
|
||
stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.
|
||
The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to term and conditions set out in
|
||
the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or
|
||
not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and Overall
|
||
Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong
|
||
Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section
|
||
headed “Underwriting { Underwriting Arrangements and Expenses { Hong Kong Public Offering { Grounds for
|
||
Termination ” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date (which is currently expected to be on
|
||
Thursday, January 8, 2026).
|
||
|
||
|
||
--- page 2 ---
|
||
2
|
||
Shenzhen Edge Medical Co., Ltd.
|
||
ʮ̡
|
||
(A joint stock company established in the People ’s Republic of China with limited liability)
|
||
GLOBAL OFFERING
|
||
Number of Offer Shares under
|
||
the Global Offering
|
||
: 27,722,200 H Shares (subject to
|
||
the Over-allotment Option)
|
||
Number of Hong Kong Offer Shares : 2,772,300 H Shares
|
||
Number of International Offer Shares : 24,949,900 H Shares (subject to
|
||
the Over-allotment Option)
|
||
Offer Price : HK$43.24 per H Share, plus brokerage of
|
||
1.0%, AFRC transaction levy of
|
||
0.00015%, SFC transaction levy of
|
||
0.0027% and Stock Exchange trading fee
|
||
of 0.00565%
|
||
Nominal value : RMB1.00 per H Share
|
||
Stock code : 2675
|
||
Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
|
||
Joint Bookrunners and Joint Lead Managers
|
||
Overall Coordinators, Joint Global Coordinators Joint Bookrunners
|
||
and Joint Lead Managers
|
||
Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager
|
||
|
||
|
||
--- page 3 ---
|
||
3
|
||
Shenzhen Edge Medical Co., Ltd.
|
||
ʮ̡
|
||
ANNOUNCEMENT OF ALLOTMENT RESULTS
|
||
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same
|
||
meanings as those defined in the prospectus dated December 30, 2025 (the “Prospectus ”) issued
|
||
by Shenzhen Edge Medical Co., Ltd. (the “Company ”).
|
||
Warning: In view of high concentration of shareholding in a small number of Shareholders,
|
||
Shareholders and prospective investors should be aware that the price of the Shares could
|
||
move substantially even with a small number of Shares traded and should exercise extreme
|
||
caution when dealing in the Shares.
|
||
SUMMARY
|
||
Company information
|
||
Stock code 2675
|
||
Stock short name EDGE MEDICAL-B
|
||
Dealings commencement date January 8, 2026*
|
||
* see note at the end of the announcement
|
||
Price Information
|
||
Final Offer Price HK$43.24
|
||
Offer Price Adjustment exercised N/A
|
||
Offer Shares and Share Capital
|
||
Number of Offer Shares 27,722,200
|
||
Number of Offer Shares in Hong Kong Public Offering 2,772,300
|
||
Number of Offer Shares in International Offering 24,949,900
|
||
Number of issued Shares upon Listing 387,722,200
|
||
Over-allocation
|
||
No. of Offer Shares over-allocated 4,158,300
|
||
Such over-allocation may be covered by exercising the Over-allotment Option or by making
|
||
purchases in the secondary market at prices that do not exceed the Offer Price or through
|
||
deferred delivery or a combination of these means. In the event the Over-allotment Option is
|
||
exercised, an announcement will be made on the Stock Exchange ’s website.
|
||
|
||
|
||
--- page 4 ---
|
||
4
|
||
Proceeds
|
||
Gross proceeds (Note) HK$1,198.7 million
|
||
Less: Estimated listing expenses payable based on
|
||
Final Offer Price
|
||
HK$(82.1) million
|
||
Net proceeds HK$1,116.6 million
|
||
Note: Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of
|
||
proceeds, please refer to the section headed “Future Plans and Use of Proceeds ” of the Prospectus. The
|
||
Company intends to apply the additional net proceeds from the exercise of the Over-allotment Option (if any)
|
||
for the purposes as set out in the section headed “Future Plans and Use of Proceeds ” of the Prospectus on a
|
||
pro rata basis. During the Track Record Period, the Company incurred HK$20.2 million of listing expenses,
|
||
among which, HK$18.5 million was charged to the consolidated statements of profit or loss of the Company.
|
||
ALLOTMENT RESULTS DETAILS
|
||
HONG KONG PUBLIC OFFERING
|
||
No. of valid applications 196,179
|
||
No. of successful applications 19,967
|
||
Subscription level 1,091.94 times
|
||
Claw-back triggered No
|
||
No. of Offer Shares initially available under the Hong
|
||
Kong Public Offering
|
||
2,772,300
|
||
% of Offer Shares under the Hong Kong Public
|
||
Offering to the Global Offering
|
||
10%
|
||
Final no. of Offer Shares under the Hong Kong Public
|
||
Offering (after over-allocation)
|
||
2,772,300
|
||
% of final no. of Offer Shares under the Hong Kong
|
||
Public Offering to the Global Offering (after over-
|
||
allocation)
|
||
8.70%
|
||
Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can
|
||
refer to http://www.hkeipo.hk/IPOResult to perform a search by identification number or
|
||
http://www.tricor.com.hk/ipo/result for the full list of allottees.
|
||
|
||
|
||
--- page 5 ---
|
||
5
|
||
INTERNATIONAL OFFERING
|
||
No. of placees 175
|
||
Subscription Level 25.18 times
|
||
No. of Offer Shares initially available under the
|
||
International Offering
|
||
24,949,900
|
||
% of Offer Shares under the International Offering to
|
||
the Global Offering
|
||
90%
|
||
Final no. of Offer Shares under the International
|
||
Offering (after over-allocation)
|
||
29,108,200
|
||
% of final no. of Offer Shares under the International
|
||
Offering to the Global Offering (after over-allocation)
|
||
91.30%
|
||
The Directors confirm that, to the best of their knowledge, information and belief, save for consent
|
||
to permit the Company to, among other things, allocate Shares in the International Offering to
|
||
certain existing Shareholders and close associates of certain existing Shareholders, (i) none of the
|
||
Offer Shares subscribed by the placees and the public have been financed directly or indirectly
|
||
by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling
|
||
shareholders, substantial shareholders, existing shareholders of the Company or any of its
|
||
subsidiaries or their respective close associates; and (ii) none of the placees and the public who
|
||
have purchased the Offer Shares are accustomed to taking instructions from the Company, any of
|
||
the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial
|
||
shareholders, existing shareholders of the Company or any of its subsidiaries or their respective
|
||
close associates in relation to the acquisition, disposal, voting or other disposition of Shares
|
||
registered in his/her/its name or otherwise held by him/her/it.
|
||
The placees in the International Offering include the following:
|
||
Cornerstone Investors
|
||
Investor Note 1
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 2
|
||
Approximate %
|
||
of total issued
|
||
share capital
|
||
after the
|
||
Global
|
||
Offering Note 2
|
||
Existing
|
||
Shareholders or
|
||
their close
|
||
associates
|
||
Abu Dhabi Investment Authority 2,699,000 9.74% 0.70% No
|
||
UBS Asset Management
|
||
(Singapore) Ltd. Note 3 1,799,300 6.49% 0.46% No
|
||
OrbiMed Genesis Master Fund, L.P. Note 4 1,799,300 6.49% 0.46% Existing
|
||
Shareholder
|
||
Huang River Investment Limited 899,600 3.25% 0.23% No
|
||
LYFE Capital Fund IV (Dragon), L.P. Note 5 899,600 3.25% 0.23%
|
||
Close associate
|
||
of an existing
|
||
shareholder
|
||
|
||
|
||
--- page 6 ---
|
||
6
|
||
Investor Note 1
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 2
|
||
Approximate %
|
||
of total issued
|
||
share capital
|
||
after the
|
||
Global
|
||
Offering Note 2
|
||
Existing
|
||
Shareholders or
|
||
their close
|
||
associates
|
||
Poly Platinum Enterprises Limited Note 6 539,800 1.95% 0.14%
|
||
Close associate
|
||
of an existing
|
||
shareholder
|
||
Mega Prime Development Limited Note 6 359,800 1.30% 0.09%
|
||
Close associate
|
||
of an existing
|
||
shareholder
|
||
China Asset Management (Hong Kong)
|
||
Limited Note 7 899,600 3.25% 0.23% No
|
||
China Alpha Fund Management (HK) Ltd 899,600 3.25% 0.23% No
|
||
Tekful Limited 539,800 1.95% 0.14% No
|
||
Integrated Core Strategies (Asia) Pte. Ltd. 539,800 1.95% 0.14% No
|
||
Sage Partners Master Fund Note 8 539,800 1.95% 0.14%
|
||
Close associate
|
||
of an existing
|
||
shareholder
|
||
Panjing Harbourview Investment Fund 539,800 1.95% 0.14% No
|
||
Infini Global Master Fund 539,800 1.95% 0.14% No
|
||
Total 13,494,600 48.68% 3.48%
|
||
Note:
|
||
1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors ” in
|
||
the Prospectus.
|
||
2. Before any exercise of the Over-allotment Option.
|
||
3. UBS Asset Management (Singapore) Ltd. ( “UBS AM Singapore ”) is a connected client of UBS AG
|
||
Singapore Branch ( “UBS AG Singapore ”). For details of consent under paragraph 1C(1) of Appendix F1 of
|
||
the Listing Rules (the “Placing Guidelines ”) in relation to allocations to connected clients as Cornerstone
|
||
Investors, please refer to the section headed “Allotment Results Details – International Offering – Allottees
|
||
with Waivers/Consents Obtained ” in this announcement.
|
||
4. OrbiMed Genesis Master Fund, L.P. ( “OrbiMed Genesis ”) and its close associate, OrbiMed New Horizons
|
||
Master Fund, L.P., are existing Shareholders of our Company, holding in aggregate approximately 0.33% of
|
||
the equity interest in the Company immediately prior to the Global Offering. For details of consent under
|
||
Rule 10.04 and paragraph 1C(2) of the Placing Guidelines for allocation of Offer Shares to a close associate
|
||
of an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results
|
||
Details – International Offering – Allottees with Waivers/Consents Obtained ” in this announcement.
|
||
|
||
|
||
--- page 7 ---
|
||
7
|
||
Investor Note 1
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 2
|
||
Approximate %
|
||
of total issued
|
||
share capital
|
||
after the
|
||
Global
|
||
Offering Note 2
|
||
Existing
|
||
Shareholders or
|
||
their close
|
||
associates
|
||
5. LYFE Capital Fund IV (Dragon), L.P. is a close associate of Guadalupe Peak Limited, which in turn holds
|
||
approximately 5.27% equity interest in the Company immediately prior to the Global Offering. For details of
|
||
consent under paragraph 1C(2) of the Placing Guidelines for allocation of Offer Shares to a close associate of
|
||
an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results Details
|
||
– International Offering – Allottees with Waivers/Consents Obtained ” in this announcement.
|
||
6. Mega Prime Development Limited and Poly Platinum Enterprises Limited are close associates of GBA Fund
|
||
Investment Limited ( “GBA Fund ”), with GBA Fund holding approximately 0.33% of the equity interest
|
||
in the Company immediately prior to the Global Offering. For details of consent under paragraph 1C(2)
|
||
of the Placing Guidelines for allocation of Offer Shares to a close associate of an existing shareholder as
|
||
Cornerstone Investor, please refer to the section headed “Allotment Results Details – International Offering –
|
||
Allottees with Waivers/Consents Obtained ” in this announcement.
|
||
7. China Asset Management (Hong Kong) Limited ( “ChinaAMC (HK) ”) is a connected client of CLSA
|
||
Limited. For details of consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to
|
||
connected clients as Cornerstone Investors, please refer to the section headed “Allotment Results Details –
|
||
International Offering – Allottees with Waivers/Consents Obtained ” in this announcement.
|
||
8. Sage Partners Master Fund is a close associate of Sage Partners Alpha 1 L.P. ( “Sage Partners ”) with Sage
|
||
Partners holding approximately 0.20% of the equity interest in the Company immediately prior to the Global
|
||
Offering. For details of consent under paragraph 1C(2) of the Placing Guidelines for allocation Offer Shares
|
||
to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed
|
||
“Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained ” in this
|
||
announcement.
|
||
Allottees with Waivers/Consents Obtained
|
||
Investor
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 1
|
||
Approximate % of
|
||
total issued
|
||
share capital after
|
||
the Global
|
||
Offering Note 1 Relationship
|
||
Allottees with consent under Rule 10.04 of the Listing Rules and/or Paragraph 1C(2) of the Placing Guidelines – Allocation of
|
||
Offer Shares to an existing shareholder and/or close associates of existing shareholders Note 2
|
||
OrbiMed Genesis 1,799,300 6.49% 0.46%
|
||
A Cornerstone
|
||
Investor, an existing
|
||
shareholder and a
|
||
close associate of an
|
||
existing shareholder
|
||
LYFE Capital Fund IV (Dragon), L.P. 899,600 3.25% 0.23%
|
||
A Cornerstone
|
||
Investor and a close
|
||
associate of an
|
||
existing shareholder
|
||
Poly Platinum Enterprises Limited 539,800 1.95% 0.14%
|
||
A Cornerstone
|
||
Investor and a close
|
||
associate of an
|
||
existing shareholder
|
||
|
||
|
||
--- page 8 ---
|
||
8
|
||
Investor
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 1
|
||
Approximate % of
|
||
total issued
|
||
share capital after
|
||
the Global
|
||
Offering Note 1 Relationship
|
||
Mega Prime Development Limited 359,800 1.30% 0.09%
|
||
A Cornerstone
|
||
Investor and a close
|
||
associate of an
|
||
existing shareholder
|
||
Sage Partners Master Fund 539,800 1.95% 0.14%
|
||
A Cornerstone
|
||
Investor and a close
|
||
associate of an
|
||
existing shareholder
|
||
3H Health Investment Fund II, L.P. 540,000 1.95% 0.14%
|
||
A placee and a close
|
||
associate of existing
|
||
shareholders
|
||
Dragon Warrior Investments Limited 90,000 0.32% 0.02%
|
||
A placee and a close
|
||
associate of existing
|
||
shareholders
|
||
GF Securities Asset Management
|
||
(Guangdong) Co., Ltd. ( “GF Securities
|
||
AM”)
|
||
1,800 0.01% 0.00%
|
||
A placee, a
|
||
connected client of
|
||
GF Securities (Hong
|
||
Kong) Brokerage
|
||
Limited ( “GF
|
||
Securities (Hong
|
||
Kong) Brokerage ”)
|
||
and a close associate
|
||
of an existing
|
||
shareholder
|
||
GF International Investment Management
|
||
Limited ( “GF International ”), 1,800 0.01% 0.00%
|
||
A placee, a
|
||
connected client of
|
||
GF Securities (Hong
|
||
Kong) Brokerage
|
||
and a close associate
|
||
of an existing
|
||
shareholder
|
||
E Fund Management Co., Ltd. ( “E Fund ”) 98,800 0.36% 0.03%
|
||
A placee, a
|
||
connected client of
|
||
GF Securities (Hong
|
||
Kong) Brokerage
|
||
and a close associate
|
||
of an existing
|
||
shareholder
|
||
|
||
|
||
--- page 9 ---
|
||
9
|
||
Investor
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 1
|
||
Approximate % of
|
||
total issued
|
||
share capital after
|
||
the Global
|
||
Offering Note 1 Relationship
|
||
E Fund Management (Hong Kong) Co., Ltd.
|
||
(“E Fund Hong Kong ”) 9,200 0.03% 0.00%
|
||
A placee, a
|
||
connected client of
|
||
GF Securities (Hong
|
||
Kong) Brokerage
|
||
and a close associate
|
||
of an existing
|
||
shareholder
|
||
Value Partners Hong Kong Limited ( “Value
|
||
Partners ”) 5,000 0.02% 0.00%
|
||
A placee, a
|
||
connected client of
|
||
GF Securities (Hong
|
||
Kong) Brokerage
|
||
and a close associate
|
||
of an existing
|
||
shareholder
|
||
Taibai Investments Pte. Ltd. 900,000 3.25% 0.23%
|
||
A placee and a close
|
||
associate of existing
|
||
shareholders
|
||
Mirae Asset Securities Co., Ltd. 3,500 0.01% 0.00%
|
||
A placee and a
|
||
close associate of an
|
||
existing shareholder
|
||
Mirae Asset Securities (HK) Limited 90,000 0.32% 0.02%
|
||
A placee and a
|
||
close associate of an
|
||
existing shareholder
|
||
CICC Financial Trading Limited 6,500 0.02% 0.00%
|
||
A placee, a
|
||
connected client of
|
||
China International
|
||
Capital Corporation
|
||
Hong Kong
|
||
Securities Limited
|
||
(“CICCHKS ”) and
|
||
a close associate
|
||
of an existing
|
||
shareholder
|
||
Note:
|
||
1. Before any exercise of the Over-allotment Option.
|
||
2. For details of the consent under Rule 10.04 of the Listing Rules and paragraph 1C(2) of the Placing
|
||
Guidelines granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the
|
||
International Offering to existing shareholders and/or close associates of existing Shareholders, please refer
|
||
to the section headed “Waivers and Exemption ” in the Prospectus and the section headed “Others/Additional
|
||
Information ” in this announcement.
|
||
|
||
|
||
--- page 10 ---
|
||
10
|
||
Investor
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 1
|
||
Approximate % of
|
||
total issued
|
||
share capital after
|
||
the Global
|
||
Offering Note 1 Relationship
|
||
Allottees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients Note 2
|
||
ChinaAMC (HK) 899,600 3.25% 0.23%
|
||
A Cornerstone Investor
|
||
and a connected client
|
||
of CLSA Limited
|
||
(“CLSA”)
|
||
GF International Investment Management Limited
|
||
( “GF International ”) 1,800 0.01% 0.00%
|
||
A placee, a connected
|
||
client of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and a close
|
||
associate of an existing
|
||
shareholder
|
||
GF Securities Asset Management (Guangdong)
|
||
Co., Ltd. ( “GF Securities AM ”) 1,800 0.01% 0.00%
|
||
A placee, a connected
|
||
client of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and a close
|
||
associate of an existing
|
||
shareholder
|
||
|
||
|
||
--- page 11 ---
|
||
11
|
||
Investor
|
||
No. of
|
||
Offer Shares
|
||
allocated
|
||
Approximate %
|
||
of Offer
|
||
Shares Note 1
|
||
Approximate % of
|
||
total issued
|
||
share capital after
|
||
the Global
|
||
Offering Note 1 Relationship
|
||
E Fund Management Co., Ltd. ( “E Fund ”) 98,800 0.36% 0.03%
|
||
A placee, a connected
|
||
client of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and a close
|
||
associate of an existing
|
||
shareholder
|
||
E Fund Management (Hong Kong) Limited
|
||
( “E Fund Hong Kong ”) 9,200 0.03% 0.00%
|
||
A placee, a connected
|
||
client of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and a close
|
||
associate of an existing
|
||
shareholder
|
||
Value Partners Hong Kong Limited
|
||
( “Value Partners ”) 5,000 0.02% 0.00%
|
||
A placee, a connected
|
||
client of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and a close
|
||
associate of an existing
|
||
shareholder
|
||
UBS Asset Management (Singapore) Ltd.
|
||
( “UBS AM Singapore ”) 1,799,300 6.49% 0.46%
|
||
A placee and a
|
||
connected client of
|
||
UBS AG Singapore
|
||
Branch ( “UBS AG
|
||
Singapore ”)
|
||
ICBC UBS Asset Management Co., Ltd.
|
||
( “ICBC UBS ”) 125,000 0.45% 0.03%
|
||
A placee and a
|
||
connected client of
|
||
UBS AG Singapore
|
||
CICC Financial Trading Limited
|
||
( “CICC FT ”) 6,500 0.02% 0.00%
|
||
A placee, a connected
|
||
client of CICCHKS and
|
||
a close associate of an
|
||
existing shareholder
|
||
CITIC Securities International Capital
|
||
Management Limited ( “CSICM ”) 741,400 2.67% 0.19%
|
||
A placee and a
|
||
connected client of
|
||
CLSA
|
||
Note:
|
||
1. Before any exercise of the Over-allotment Option.
|
||
2. For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to
|
||
connected clients, please refer to the section headed “Waivers and Exemption ” in the Prospectus and the
|
||
section headed “Others/Additional Information ” in this announcement.
|
||
|
||
|
||
--- page 12 ---
|
||
12
|
||
LOCK-UP UNDERTAKINGS
|
||
Controlling Shareholders
|
||
Name
|
||
Number of shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing Note 1
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings
|
||
Dr. Wang Note 2 31,368,798 Unlisted Shares
|
||
73,193,861 H Shares 26.97% January 8, 2027 Note 3
|
||
Dr. Gao Note 2 15,500,065 Unlisted Shares
|
||
36,166,819 H Shares 13.33% January 8, 2027 Note 3
|
||
Xieli Chuangfeng Note 2 10,708,126 H Shares 2.76% January 8, 2027 Note 3
|
||
Subtotal 166,937,669 43.06%
|
||
Notes:
|
||
(1) Before any exercise of the Over-allotment Option.
|
||
(2) Dr. Wang is the sole general partner of Xieli Chuangfeng. By virtue of their spousal relationship, Dr. Wang
|
||
and Dr. Gao, together with Xieli Chuangfeng (an entity controlled by Dr. Wang) form a group of Controlling
|
||
Shareholders of our Company upon Listing.
|
||
(3) The expiry day of the lock-up period shown in the table above is pursuant to the PRC Company Law. In
|
||
accordance with the relevant Listing Rule and guidance materials, the required lock-up for the First Six-
|
||
Month Period ends on July 8, 2026 and the Second Six-Month Period ends on January 8, 2027.
|
||
Pre-IPO Investors
|
||
Name
|
||
Number of shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing Note 1
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings
|
||
Chengdu Mingsheng 17,504,640 H Shares 4.51% January 8, 2027 Note 2
|
||
Zhongheng Huijin 16,359,120 H Shares 4.22% January 8, 2027 Note 2
|
||
Suzhou Junlian 701,778 Unlisted Shares
|
||
11,787,990 H Shares 3.22% January 8, 2027 Note 2
|
||
Sanzheng Zhengyun 11,691,424 H Shares 3.02% January 8, 2027 Note 2
|
||
Social Security Fund 272,913 Unlisted Shares
|
||
4,584,216 H Shares 1.25% January 8, 2027 Note 2
|
||
|
||
|
||
--- page 13 ---
|
||
13
|
||
Name
|
||
Number of shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing Note 1
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings
|
||
Shenzhen Zhihui 4,473,922 H Shares 1.15% January 8, 2027 Note 2
|
||
Khorgos Lianpan 4,892,760 H Shares 1.26% January 8, 2027 Note 2
|
||
Beijing Xinghao 4,892,760 H Shares 1.26% January 8, 2027 Note 2
|
||
HongShan Growth 1,290,060 Unlisted Shares
|
||
3,010,140 H Shares 1.11% January 8, 2027 Note 2
|
||
Taijiashan Healthcare Fund 1,318,189 Unlisted Shares
|
||
3,075,775 H Shares 1.13% January 8, 2027 Note 2
|
||
Shenzhen Hanchen 1,318,189 Unlisted Shares
|
||
3,075,775 H Shares 1.13% January 8, 2027 Note 2
|
||
Guoce Green Technology 3,998,261 H Shares 1.03% January 8, 2027 Note 2
|
||
Guoce Technology Manufacturing 2,817,275 H Shares 0.73% January 8, 2027 Note 2
|
||
Jiaxing Siqi 333,586 H Shares 0.09% January 8, 2027 Note 2
|
||
Jiaxing Yusheng 168,360 H Shares 0.04% January 8, 2027 Note 2
|
||
Lingang Lanwan Fund I 2,388,960 H Shares 0.62% January 8, 2027 Note 2
|
||
China State-owned Enterprise Mixed
|
||
Ownership Reform Fund 1,911,240 H Shares 0.49% January 8, 2027 Note 2
|
||
Vertex Investment 441,270 Unlisted Shares
|
||
1,323,810 H Shares 0.46% January 8, 2027 Note 2
|
||
Beijing Yahui Jinlin 1,715,040 H Shares 0.44% January 8, 2027 Note 2
|
||
Yu Anding (֛1,476,720 H Shares 0.38% January 8, 2027 Note 2
|
||
Hainan Yuanfeng 1,466,280 H Shares 0.38% January 8, 2027 Note 2
|
||
Hangzhou Kangyin 1,466,280 H Shares 0.38% January 8, 2027 Note 2
|
||
CICC Pucheng 1,466,280 H Shares 0.38% January 8, 2027 Note 2
|
||
Chengdu Boyuan Jiayu 1,466,280 H Shares 0.38% January 8, 2027 Note 2
|
||
Wuxi FirstLight 1,194,480 H Shares 0.31% January 8, 2027 Note 2
|
||
Guangyuan Zhonghe 1,168,560 H Shares 0.30% January 8, 2027 Note 2
|
||
Jiaxing Suizi 944,216 H Shares 0.24% January 8, 2027 Note 2
|
||
Fan Xiaolin (ወᎌ) 716,760 H Shares 0.18% January 8, 2027 Note 2
|
||
|
||
|
||
--- page 14 ---
|
||
14
|
||
Name
|
||
Number of shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing Note 1
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings
|
||
Qingdao Yizhou 716,760 H Shares 0.18% January 8, 2027 Note 2
|
||
Hangzhou Xiangshu 477,720 H Shares 0.12% January 8, 2027 Note 2
|
||
Guangzhou Jinyuan 422,071 H Shares 0.11% January 8, 2027 Note 2
|
||
Jiang Hao (۴372,960 H Shares 0.10% January 8, 2027 Note 2
|
||
Guadalupe Peak Limited
|
||
4,741,110 Unlisted
|
||
Shares
|
||
14,223,330 H Shares
|
||
4.89% January 8, 2027 Note 2
|
||
Intelligent Spark
|
||
4,300,128 Unlisted
|
||
Shares
|
||
10,033,632 H Shares
|
||
3.70% January 8, 2027 Note 2
|
||
Spark Plug 2,388,960 H Shares 0.62% January 8, 2027 Note 2
|
||
Robust Edge Investments 10,563,551 H Shares 2.72% January 8, 2027 Note 2
|
||
Centroid Investments 8,386,920 H Shares 2.16% January 8, 2027 Note 2
|
||
Springleaf Investments
|
||
2,293,380 Unlisted
|
||
Shares
|
||
5,351,220 H Shares
|
||
1.97% January 8, 2027 Note 2
|
||
True Light 573,372 Unlisted Shares
|
||
1,337,868 H Shares 0.49% January 8, 2027 Note 2
|
||
Kangji Medical 5,865,840 H Shares 1.51% January 8, 2027 Note 2
|
||
GBA Fund 1,194,480 H Shares 0.31% January 8, 2027 Note 2
|
||
Sage Partners 716,760 H Shares 0.18% January 8, 2027 Note 2
|
||
Octagon Investments 716,760 H Shares 0.18% January 8, 2027 Note 2
|
||
OrbiMed Genesis 597,240 H Shares 0.15% January 8, 2027 Note 2
|
||
OrbiMed New Horizons 597,240 H Shares 0.15% January 8, 2027 Note 2
|
||
Mirae Asset Global Investments 477,720 H Shares 0.12% January 8, 2027 Note 2
|
||
Subtotal 193,062,331 49.79%
|
||
Notes:
|
||
(1) Before any exercise of the Over-allotment Option.
|
||
(2) The expiry day of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
|
||
|
||
--- page 15 ---
|
||
15
|
||
Cornerstone Investors
|
||
Name
|
||
Number of H Shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of shareholding
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings
|
||
upon Listing Note 1
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings
|
||
Abu Dhabi Investment Authority 2,699,000 0.70% July 8, 2026 Note 2
|
||
UBS Asset Management (Singapore) Ltd. 1,799,300 0.46% July 8, 2026 Note 2
|
||
OrbiMed Genesis Master Fund, L.P. 1,799,300 0.46% July 8, 2026 Note 2
|
||
Huang River Investment Limited 899,600 0.23% July 8, 2026 Note 2
|
||
China Asset Management (Hong Kong) Limited 899,600 0.23% July 8, 2026 Note 2
|
||
LYFE Capital Fund IV (Dragon), L.P. 899,600 0.23% July 8, 2026 Note 2
|
||
Poly Platinum Enterprises Limited 539,800 0.14% July 8, 2026 Note 2
|
||
Mega Prime Development Limited 359,800 0.09% July 8, 2026 Note 2
|
||
China Alpha Fund Management (HK) Ltd 899,600 0.23% July 8, 2026 Note 2
|
||
Tekful Limited 539,800 0.14% July 8, 2026 Note 2
|
||
Integrated Core Strategies (Asia) Pte. Ltd. 539,800 0.14% July 8, 2026 Note 2
|
||
Sage Partners Master Fund 539,800 0.14% July 8, 2026 Note 2
|
||
Panjing Harbourview Investment Fund 539,800 0.14% July 8, 2026 Note 2
|
||
Infini Global Master Fund 539,800 0.14% July 8, 2026 Note 2
|
||
Total 13,494,600 3.48%
|
||
Notes:
|
||
(1) Before any exercise of the Over-allotment Option.
|
||
(2) The expiry day of the lock-up period shown in the table above is pursuant to the relevant Cornerstone
|
||
Investment Agreements.
|
||
|
||
|
||
--- page 16 ---
|
||
16
|
||
PLACEE CONCENTRATION ANALYSIS
|
||
Placees*
|
||
Number of
|
||
H Shares allotted
|
||
Allotment as %
|
||
of International
|
||
Offering (assuming
|
||
no exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of International
|
||
Offering (assuming
|
||
the Over-
|
||
allotment Option
|
||
is fully
|
||
exercised and new
|
||
H Shares are
|
||
issued)
|
||
Allotment as % of
|
||
total Offer Shares
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares (assuming
|
||
the Over-
|
||
allotment
|
||
Option is fully
|
||
exercised and new
|
||
H Shares are
|
||
issued)
|
||
Number of
|
||
Shares held
|
||
upon Listing
|
||
Number of
|
||
Shares held
|
||
upon Listing as
|
||
% of total issued
|
||
share capital upon
|
||
Listing
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Number of
|
||
Shares held
|
||
upon Listing as %
|
||
of total issued
|
||
share capital
|
||
upon Listing
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and new
|
||
H Shares are
|
||
issued)
|
||
Top 1 2,699,000 10.8% 9.3% 9.7% 8.5% 2,699,000 0.7% 0.7%
|
||
Top 5 8,963,600 35.9% 30.8% 32.3% 28.1% 10,158,080 2.6% 2.6%
|
||
Top 10 13,462,400 54.0% 46.2% 48.6% 42.2% 44,371,640 11.4% 11.3%
|
||
Top 25 22,392,700 89.8% 76.9% 80.8% 70.2% 83,943,835 21.7% 21.4%
|
||
Note:
|
||
* Ranking of placees is based on the number of Shares allotted to the placees.
|
||
|
||
|
||
--- page 17 ---
|
||
17
|
||
H SHAREHOLDER CONCENTRATION ANALYSIS
|
||
H Shareholders*
|
||
Number of
|
||
H Shares
|
||
allotted
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Number of
|
||
H Shares held
|
||
upon Listing
|
||
Number of
|
||
H Shares held
|
||
upon Listing as
|
||
% of total issued
|
||
H share capital
|
||
upon Listing
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Number of
|
||
H Shares held
|
||
upon Listing as
|
||
% of total
|
||
issued H share
|
||
capital upon
|
||
Listing
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Number of
|
||
Shares held
|
||
upon Listing
|
||
Top 1 – 0.0% 0.0% 0.0% 0.0% 120,068,806 37.1% 36.6% 166,937,669
|
||
Top 5 746,600 3.0% 2.6% 2.7% 2.3% 202,861,827 62.7% 61.9% 250,705,381
|
||
Top 10 2,546,200 10.2% 8.7% 9.2% 8.0% 254,490,247 78.6% 77.6% 318,168,229
|
||
Top 25 11,515,900 46.2% 39.6% 41.5% 36.1% 299,316,631 92.5% 91.3% 362,994,613
|
||
Note:
|
||
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholder upon Listing.
|
||
|
||
|
||
--- page 18 ---
|
||
18
|
||
SHAREHOLDER CONCENTRATION ANALYSIS
|
||
Shareholders*
|
||
Number of
|
||
H Shares allotted
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of International
|
||
Offering
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and new
|
||
Shares are
|
||
issued)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and
|
||
new Shares
|
||
are issued)
|
||
Number of
|
||
Shares held
|
||
upon Listing
|
||
Number of
|
||
Shares held upon
|
||
Listing as %
|
||
of total issued
|
||
share capital
|
||
upon Listing
|
||
(assuming no
|
||
exercise of the
|
||
Over-allotment
|
||
Option)
|
||
Number of
|
||
Shares held upon
|
||
Listing as %
|
||
of total issued
|
||
share capital
|
||
upon Listing
|
||
(assuming the
|
||
Over-allotment
|
||
Option is fully
|
||
exercised and
|
||
new Shares
|
||
are issued)
|
||
Top 1 – 0.0% 0.0% 0.0% 0.0% 166,937,669 43.1% 42.6%
|
||
Top 5 1,646,200 6.6% 5.7% 5.9% 5.2% 253,222,524 65.3% 64.6%
|
||
Top 10 2,546,200 10.2% 8.7% 9.2% 8.0% 318,168,229 82.1% 81.2%
|
||
Top 25 11,515,900 46.2% 39.6% 41.5% 36.1% 363,293,413 93.7% 92.7%
|
||
Note:
|
||
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
|
||
|
||
|
||
--- page 19 ---
|
||
19
|
||
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
|
||
Subject to the satisfaction of the conditions set out in the Prospectus, 19,967 valid applications
|
||
made by the public will be conditionally allocated on the basis set out below:
|
||
Number of
|
||
H Shares
|
||
applied for
|
||
Number of
|
||
valid applications
|
||
Basis of
|
||
allocation/ballot
|
||
Approximate %
|
||
allotted of the total
|
||
no. of H Shares
|
||
applied for
|
||
POOL A
|
||
100 91,082 456 out of 91,082 applicants to
|
||
receive 100 H Shares
|
||
0.50%
|
||
200 28,073 242 out of 28,073 applicants to
|
||
receive 100 H Shares
|
||
0.43%
|
||
300 3,955 47 out of 3,955 applicants to
|
||
receive 100 H Shares
|
||
0.40%
|
||
400 1,934 29 out of 1,934 applicants to
|
||
receive 100 H Shares
|
||
0.37%
|
||
500 2,746 49 out of 2,746 applicants to
|
||
receive 100 H Shares
|
||
0.36%
|
||
600 1,206 25 out of 1,206 applicants to
|
||
receive 100 H Shares
|
||
0.35%
|
||
700 957 22 out of 957 applicants to receive
|
||
100 H Shares
|
||
0.33%
|
||
800 1,046 27 out of 1,046 applicants to
|
||
receive 100 H Shares
|
||
0.32%
|
||
900 771 22 out of 771 applicants to receive
|
||
100 H Shares
|
||
0.32%
|
||
1,000 17,714 532 out of 17,714 applicants to
|
||
receive 100 H Shares
|
||
0.30%
|
||
1,500 2,607 108 out of 2,607 applicants to
|
||
receive 100 H Shares
|
||
0.28%
|
||
2,000 4,622 238 out of 4,622 applicants to
|
||
receive 100 H Shares
|
||
0.26%
|
||
2,500 2,431 149 out of 2,431 applicants to
|
||
receive 100 H Shares
|
||
0.25%
|
||
3,000 1,627 115 out of 1,627 applicants to
|
||
receive 100 H Shares
|
||
0.24%
|
||
3,500 894 72 out of 894 applicants to receive
|
||
100 H Shares
|
||
0.23%
|
||
4,000 1,004 89 out of 1,004 applicants to
|
||
receive 100 H Shares
|
||
0.22%
|
||
4,500 811 79 out of 811 applicants to receive
|
||
100 H Shares
|
||
0.22%
|
||
5,000 1,853 195 out of 1,853 applicants to
|
||
receive 100 H Shares
|
||
0.21%
|
||
6,000 1,167 142 out of 1,167 applicants to
|
||
receive 100 H Shares
|
||
0.20%
|
||
7,000 947 130 out of 947 applicants to
|
||
receive 100 H Shares
|
||
0.20%
|
||
|
||
|
||
--- page 20 ---
|
||
20
|
||
Number of
|
||
H Shares
|
||
applied for
|
||
Number of
|
||
valid applications
|
||
Basis of
|
||
allocation/ballot
|
||
Approximate %
|
||
allotted of the total
|
||
no. of H Shares
|
||
applied for
|
||
POOL A
|
||
8,000 872 132 out of 872 applicants to
|
||
receive 100 H Shares
|
||
0.19%
|
||
9,000 686 114 out of 686 applicants to
|
||
receive 100 H Shares
|
||
0.18%
|
||
10,000 5,686 1,024 out of 5,686 applicants to
|
||
receive 100 H Shares
|
||
0.18%
|
||
20,000 3,901 1,205 out of 3,901 applicants to
|
||
receive 100 H Shares
|
||
0.15%
|
||
30,000 2,405 1,019 out of 2,405 applicants to
|
||
receive 100 H Shares
|
||
0.14%
|
||
40,000 1,268 672 out of 1,268 applicants to
|
||
receive 100 H Shares
|
||
0.13%
|
||
50,000 1,324 835 out of 1,324 applicants to
|
||
receive 100 H Shares
|
||
0.13%
|
||
60,000 797 579 out of 797 applicants to
|
||
receive 100 H Shares
|
||
0.12%
|
||
70,000 686 562 out of 686 applicants to
|
||
receive 100 H Shares
|
||
0.12%
|
||
80,000 557 507 out of 557 applicants to
|
||
receive 100 H Shares
|
||
0.11%
|
||
90,000 455 100 H Shares 0.11%
|
||
100,000 3,693 100 H Shares plus 297 out of
|
||
3,693 applicants to receive an
|
||
additional 100 H Shares
|
||
0.11%
|
||
Total 189,777 Total number of Pool A successful applicants: 13,565
|
||
|
||
|
||
--- page 21 ---
|
||
21
|
||
Number of
|
||
H Shares
|
||
applied for
|
||
Number of
|
||
valid applications
|
||
Basis of
|
||
allocation/ballot
|
||
Approximate %
|
||
allotted of the total
|
||
no. of H Shares
|
||
applied for
|
||
POOL B
|
||
200,000 4,438 100 H Shares plus 3,551 out of
|
||
4,438 applicants to receive an
|
||
additional 100 H Shares
|
||
0.09%
|
||
300,000 769 200 H Shares plus 165 out of
|
||
769 applicants to receive an
|
||
additional 100 H Shares
|
||
0.07%
|
||
400,000 315 200 H Shares plus 178 out of
|
||
315 applicants to receive an
|
||
additional 100 H Shares
|
||
0.06%
|
||
500,000 209 200 H Shares plus 183 out of
|
||
209 applicants to receive an
|
||
additional 100 H Shares
|
||
0.06%
|
||
600,000 113 300 H Shares 0.05%
|
||
700,000 85 300 H Shares plus 26 out of
|
||
85 applicants to receive an
|
||
additional 100 H Shares
|
||
0.05%
|
||
800,000 66 300 H Shares plus 45 out of
|
||
66 applicants to receive an
|
||
additional 100 H Shares
|
||
0.05%
|
||
900,000 30 300 H Shares plus 25 out of
|
||
30 applicants to receive an
|
||
additional 100 H Shares
|
||
0.04%
|
||
1,000,000 92 400 H Shares 0.04%
|
||
1,386,100 285 400 H Shares plus 274 out of
|
||
285 applicants to receive an
|
||
additional 100 H Shares
|
||
0.04%
|
||
Total 6,402 Total number of Pool B successful applicants: 6,402
|
||
COMPLIANCE WITH LISTING RULES AND GUIDANCE
|
||
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
|
||
which consent has been obtained, the Company has complied with the Listing Rules and guidance
|
||
materials in relation to the placing, allotment and listing of the H Shares.
|
||
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees
|
||
or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or
|
||
purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC
|
||
transaction levy, SFC transaction levy and Stock Exchange trading fee payable.
|
||
|
||
|
||
--- page 22 ---
|
||
22
|
||
OTHER INFORMATION
|
||
Consent under Rule 10.04 and/or paragraph 1C(2) of the Placing Guidelines – Allocation of
|
||
Offer Shares to an existing shareholder and/or close associates of existing shareholders as
|
||
cornerstone investors
|
||
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to
|
||
the Company, consent under Rule 10.04 of the Listing Rules Paragraph 1C(2) of the Placing
|
||
Guidelines for the allocation of Offer Shares to (i) OrbiMed Genesis, (ii) Mega Prime Development
|
||
Limited and Poly Platinum Enterprises Limited, (iii) LYFE Capital Fund IV (Dragon), L.P. and (iv)
|
||
Sage Partners Master Fund as Cornerstone Investors under the Global Offering. Please refer to the
|
||
section headed “Waivers and Exemption – Waiver and consent under Rule 10.04 and Paragraph
|
||
1C(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by existing
|
||
shareholder and close associates of existing shareholder as cornerstone investors ” in the Prospectus
|
||
for details.
|
||
Consent under paragraph 1C(2) of the Placing Guidelines – Allocation of Offer Shares to
|
||
close associates of existing shareholders as placees
|
||
The Company has applied to the Stock Exchange, and the Stock Exchange has granted a consent
|
||
under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer
|
||
Shares in the International Offering to the close associates of existing shareholders as placees
|
||
(together, the “Close Associates of Existing Shareholders as Placees ”). Each of 3H Health
|
||
Investment Fund II, L.P. and Dragon Warrior Investments Limited is a close associate of Robust
|
||
Edge Investments Limited and Centroid Investments Limited. Each of GF Securities AM, GF
|
||
International, E Fund, E Fund Hong Kong and Value Partners is a close associate of Guangfa
|
||
Xinde Zhongheng Huijin (Longyan) Equity Investment Partnership (Limited Partnership) ( ᄿ
|
||
ږ( ֧)ᛆҳ༟ΥྫΆุ (Υྫ )). Taibai Investments Pte. Ltd. is a close
|
||
associate of Springleaf Investments Pte. Ltd. and True Light Investments P Pte. Ltd.. Each of
|
||
Mirae Asset Securities Co., Ltd. and Mirae Asset Securities (HK) Limited is a close associate of
|
||
Mirae Asset Global Investments (Hong Kong) Limited. CICC FT is a close associate of CICC
|
||
Pucheng Investment Co., Ltd. (ʮ̡ ). The allocation of Offer Shares to the
|
||
Close Associates of Existing Shareholders as Placees is in compliance with all the conditions under
|
||
the consent granted by the Stock Exchange, including but not limited to (i) the Company complies
|
||
with Rules 19A.13A and 19A.13C of the Listing Rules, and (ii) no preference in allocation was
|
||
given to the Close Associates of Existing Shareholders as Placees.
|
||
For details of the allocations of Offer Shares to close associates of existing Shareholders, please
|
||
refer to the section headed “Allotment Results Details { International Offering { Allotees with
|
||
Waivers/Consents Obtained ” in this announcement.
|
||
Placing to connected clients with prior consents under paragraph 1C(1) of the Placing
|
||
Guidelines
|
||
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted,
|
||
consents under paragraph 1C(1) of the Placing Guidelines to permit allocation to connected clients
|
||
pursuant to the Placing Guidelines. The allocation of Offer Shares to such connected clients is in
|
||
compliance with all the conditions under the consents granted by the Stock Exchange. Details of
|
||
the placement to connected clients in placing tranche are set out below.
|
||
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted a
|
||
consent under paragraph 1C(1) of the Placing Guidelines to permit ChinaAMC (HK) to participate
|
||
in the Global Offering as a Cornerstone Investor and connected client holding the Offer Shares
|
||
on a discretionary basis. Please refer to the section headed “Waivers and Exemption – Consent in
|
||
respect of the proposed subscription of Offer Shares by Connected Client ” in the Prospectus for
|
||
details.
|
||
|
||
|
||
--- page 23 ---
|
||
23
|
||
In addition, the Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the
|
||
Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to connected clients. The allocation
|
||
of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by the Stock Exchange. Details
|
||
of the placement to the connected clients are set out below.No.
|
||
Name of connected
|
||
client
|
||
Name of connected
|
||
distributor
|
||
Relationship with the connected distributor
|
||
Basis of holding
|
||
securities
|
||
Number of Offer Shares subscribed
|
||
Approximate percentage of the Offer Shares subscribed (assuming the Over-allotment
|
||
Option is not exercised)
|
||
Approximate
|
||
percentage of total issued share capital after the Global
|
||
Offering (assuming no exercise of the Over-allotment Option)
|
||
1. GF International (1)
|
||
(as placee)
|
||
GF Securities (Hong Kong)
|
||
Brokerage, one of the
|
||
Overall Coordinators
|
||
GF International is a
|
||
member of the same
|
||
group of companies as GF
|
||
Securities (Hong Kong)
|
||
Brokerage.
|
||
Discretionary 1,800 0.01% 0.00%
|
||
2. GF Securities AM (2)
|
||
(as placee)
|
||
GF Securities (Hong Kong)
|
||
Brokerage, one of the
|
||
Overall Coordinators
|
||
GF Securities AM is
|
||
a member of the same
|
||
group of companies as GF
|
||
Securities (Hong Kong)
|
||
Brokerage.
|
||
Non-discretionary 1,800 0.01% 0.00%
|
||
3. E Fund (3) (as placee) GF Securities (Hong Kong)
|
||
Brokerage, one of the
|
||
Overall Coordinators
|
||
E Fund is a member of the
|
||
same group of companies as
|
||
GF Securities (Hong Kong)
|
||
Brokerage.
|
||
Discretionary 98,800 0.36% 0.03%
|
||
4. E Fund Hong
|
||
Kong(4) (as placee)
|
||
GF Securities (Hong Kong)
|
||
Brokerage, one of the
|
||
Overall Coordinators
|
||
E Fund Hong Kong is
|
||
a member of the same
|
||
group of companies as GF
|
||
Securities (Hong Kong)
|
||
Brokerage.
|
||
Discretionary 9,200 0.03% 0.00%
|
||
5. Value Partners (5) (as
|
||
placee)
|
||
GF Securities (Hong Kong)
|
||
Brokerage, one of the
|
||
Overall Coordinators
|
||
Value Partners is a member
|
||
of the same group of
|
||
companies as GF Securities
|
||
(Hong Kong) Brokerage.
|
||
Discretionary 5,000 0.02% 0.00%
|
||
|
||
|
||
--- page 24 ---
|
||
24
|
||
No.
|
||
Name of connected
|
||
client
|
||
Name of connected
|
||
distributor
|
||
Relationship with the connected distributor
|
||
Basis of holding
|
||
securities
|
||
Number of Offer Shares subscribed
|
||
Approximate percentage of the Offer Shares subscribed (assuming the Over-allotment
|
||
Option is not exercised)
|
||
Approximate
|
||
percentage of total issued share capital after the Global
|
||
Offering (assuming no exercise of the Over-allotment Option)
|
||
6. UBS AM
|
||
Singapore (6)
|
||
(as cornerstone
|
||
investor)
|
||
UBS AG Singapore, one
|
||
of the distributors of the
|
||
Global Offering
|
||
UBS AM Singapore is a
|
||
member of the same group
|
||
of companies as UBS AG
|
||
Singapore.
|
||
Discretionary 1,799,300 6.49% 0.46%
|
||
7. ICBC UBS (7) (as
|
||
placee)
|
||
UBS AG Singapore, one
|
||
of the distributors of the
|
||
Global Offering
|
||
ICBC UBS is a member
|
||
of the same group of
|
||
companies as UBS AG
|
||
Singapore.
|
||
Discretionary 125,000 0.45% 0.03%
|
||
8. CICC FT (8) (as
|
||
placee)
|
||
CICCHKS, one of the
|
||
Overall Coordinators
|
||
CICC FT is a member of the
|
||
same group of companies as
|
||
CICCHKS.
|
||
Non-discretionary 6,500 0.02% 0.00%
|
||
9. CSICM(9) (as
|
||
placee)
|
||
CLSA, one of the Overall
|
||
Coordinators
|
||
CSICM is a member of the
|
||
same group of companies as
|
||
CLSA.
|
||
Non-discretionary 741,400
|
||
Shenzhen Commando:
|
||
36,000
|
||
Beevest:
|
||
700,000
|
||
Perseverance AM:
|
||
5,400
|
||
2.67%
|
||
Shenzhen Commando:
|
||
0.13%
|
||
Beevest:
|
||
2.53%
|
||
Perseverance AM:
|
||
0.02%
|
||
0.19%
|
||
Shenzhen Commando:
|
||
0.01%
|
||
Beevest:
|
||
0.18%
|
||
Perseverance AM:
|
||
0.00%
|
||
Notes:
|
||
(1) GF International will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of their underlying clients (the “GF International
|
||
Ultimate Clients ”), each of which is an independent third party. Save for Ku Sen ( ᚥો), none of the GF International Ultimate Clients holds 30% or more
|
||
ultimate beneficial interest in the relevant funds. GF International has confirmed that, to the best of their knowledge, each of the GF International Ultimate
|
||
Clients is an independent party of GF International, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies
|
||
as GF Securities (Hong Kong) Brokerage.
|
||
(2) GF Securities AM is an asset manager that is a QDII as approved by the relevant authority and will hold the Offer Shares as product manager on behalf of GF
|
||
Asset Management Excellent Diversified Allocation No. 10 (QDII) Single Asset Management Plan ( ᄿ೯༟၍ՙ൳εʩৣໄ 10 (QDII)ྌ ),
|
||
with the ultimate client being Feng Tianhong (ߎ࠺the “GF Securities AM Ultimate Client ”). GF Securities AM has confirmed that, to the best of their
|
||
knowledge, the GF Securities AM Ultimate Client is an independent party of GF Securities AM, GF Securities (Hong Kong) Brokerage and the companies which
|
||
are members of the same group of companies as GF Securities (Hong Kong) Brokerage.
|
||
|
||
|
||
--- page 25 ---
|
||
25
|
||
(3) E Fund will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of their underlying
|
||
clients (the “E Fund Ultimate Clients ”), each of which is an independent third party. None of the E Fund
|
||
Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds. E Fund has confirmed
|
||
that, to the best of their knowledge, each of the E Fund Ultimate Clients is an independent party of E Fund, GF
|
||
Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as
|
||
GF Securities (Hong Kong) Brokerage.
|
||
(4) E Fund Hong Kong will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of
|
||
their underlying clients (the “E Fund Hong Kong Ultimate Clients ”), each of which is an independent third
|
||
party. None of the E Fund Hong Kong Ultimate Clients holds more than 30% ultimate beneficial interest in the
|
||
relevant funds. E Fund Hong Kong has confirmed that, to the best of their knowledge, each of the E Fund Hong
|
||
Kong Ultimate Clients is an independent party of E Fund Hong Kong, GF Securities (Hong Kong) Brokerage
|
||
and the companies which are members of the same group of companies as GF Securities (Hong Kong)
|
||
Brokerage.
|
||
(5) Value Partners will hold the Offer Shares in its capacity as the discretionary fund manager managing the
|
||
SFC-authorized funds on behalf of their underlying clients (the “Value Partners Ultimate Clients ”), each of
|
||
which is an independent third party. The ultimate beneficial owners holding 30% or more interest in the SFC-
|
||
authorized collective authorized schemes are set out below:
|
||
(i) AIA International Limited
|
||
(ii) Bank of China (Hong Kong) Nominees Limited
|
||
(iii) The Master Trust Bank of Japan Limited.
|
||
Value Partners has confirmed that, to the best of their knowledge, each of the Value Partners Ultimate Clients
|
||
is an independent party of Value Partners, GF Securities (Hong Kong) Brokerage and the companies which are
|
||
members of the same group of companies as GF Securities (Hong Kong) Brokerage.
|
||
(6) UBS AM Singapore will hold the Offer Shares in its capacity as the discretionary fund manager managing
|
||
the funds on behalf of their investors (the “UBS AM Singapore Ultimate Clients ”), each of which is an
|
||
independent third party. None of the UBS AM Singapore Ultimate Clients holds more than 30% ultimate
|
||
beneficial interest in the relevant funds. UBS AM Singapore has confirmed that, to the best of their knowledge,
|
||
each of the UBS AM Singapore Ultimate Clients is an independent party of UBS AM Singapore, UBS AG
|
||
Singapore and the companies which are members of the same group of companies as UBS AG.
|
||
(7) ICBC UBS will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds
|
||
on behalf of their investors (the “ICBC UBS Ultimate Clients ”), each of which is an independent third party.
|
||
None of the ICBC UBS Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds.
|
||
ICBC UBS has confirmed that, to the best of their knowledge, each of the ICBC UBS Ultimate Clients is an
|
||
independent party of ICBC UBS, UBS AG Singapore and the companies which are members of the same group
|
||
of companies as UBS AG.
|
||
|
||
|
||
--- page 26 ---
|
||
26
|
||
(8) CICC FT and China International Capital Corporation Limited will enter into a series of cross border delta-one
|
||
OTC swap transactions (collectively, the “CICC OTC Swaps ”) with each other and the ultimate client (the
|
||
“CICC FT Ultimate Client ”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary
|
||
basis to hedge the CICC OTC Swaps while the economic risks and returns of the underlying Offer Shares are
|
||
passed to the CICC FT Ultimate Client, subject to customary fees and commissions. The CICC OTC Swaps
|
||
will be fully funded by the CICC FT Ultimate Client. During the terms of the CICC OTC Swaps, all economic
|
||
returns of the Offer Shares subscribed by CICC FT will be passed to the CICC FT Ultimate Client and all
|
||
economic loss shall be borne by the CICC FT Ultimate Client through the CICC OTC Swaps, and CICC FT
|
||
will not take part in any economic return or bear any economic loss in relation to the Offer Shares. Despite that
|
||
CICC FT will hold the legal title of the Offer Shares by itself, it will not exercise the voting rights attaching
|
||
to the relevant Offer Shares during the terms of the CICC OTC Swaps according to its internal policy. The
|
||
CICC FT Ultimate Client is Shanghai Baoyin Private Equity Fund Management Co., Ltd. (ږ
|
||
ʮ̡ ) ( “Pinpoint Fund ”), which in turn manages the funds Baoyin Duokong Wenjian No. 1 Private
|
||
Equity Investment Fund (ᖢ 1ږ“( ) Duokong Wenjian No. 1 ”), Baoyin Duokong
|
||
Wenjian No. 2 Private Equity Investment Fund (ᖢ 2ږDuokong Wenjian
|
||
No. 2 ”) and Baoyin Jinqu No. 1 Private Equity Investment Fund (ვආ՟ 1ږJinqu
|
||
No. 1 ”). The ultimate beneficial owner holding 30% or more interest in Duokong Wenjian No. 1 and Duokong
|
||
Wenjian No. 2 is. Wang Qiang ( ˮ੶), with no other ultimate beneficial owners holding 30% or more interest
|
||
in Duokong Wenjian No.1, Duokong Wenjian No. 2 and Jinqu No.1. To the best of CICC FT ’s knowledge, after
|
||
making all reasonable inquiries, each of the CICC FT Ultimate Client and its ultimate beneficial owner is a third
|
||
party independent from CICC FT and CICCHKS and the companies which are members of the same group of
|
||
companies as CICCHKS.
|
||
(9) CSICM will act as the single counterparty of a back-to-back total return swap transaction (the “CSICM
|
||
Back-to-back TRS ”) to be entered into by CSICM in connection with a total return swap order (the “CSICM
|
||
Client TRS ”) placed by its ultimate clients (the “CSICM Ultimate Clients ”), by which CSICM will pass the
|
||
full economic exposure of the Offer Shares placed to CSICM (the “CSICM Offer Shares ”) to the CSICM
|
||
Ultimate Client, meaning in effect, CSICM will hold the beneficial interest of the CSICM Offer Shares on
|
||
behalf of the CSICM Ultimate Clients on a non-discretionary basis. CSICM will hold the legal title and
|
||
beneficial interest in the CSICM Offer Shares, but will contractually agree to pass on the full economic
|
||
exposure and return of the CSICM Offer Shares to the CSICM Ultimate Clients. The CSICM Ultimate Clients
|
||
may exercise an early termination right to early terminate the CSICM Client TRS at any time from the trade
|
||
date of the CSICM Client TRS which should be on or after the date on which the CSICM Offer Shares are listed
|
||
on the Stock Exchange. Upon the final maturity or early termination of the CSICM Client TRS by the CSICM
|
||
Ultimate Clients, CSICM will dispose of the CSICM Offer Shares on the secondary market and the CSICM
|
||
Ultimate Clients will receive a final termination amount of the CSICM Back-to-back TRS which should have
|
||
taken into account all the economic returns or economic loss in relation to the CSICM Offer Shares and the
|
||
fixed amount of transaction fees of the CSICM Back-to back TRS and the CSICM Client TRS. CSICM will not
|
||
exercise the voting right of the CSICM Offer Shares during the tenor of the CSICM Back-to-back TRS. The
|
||
CSICM Ultimate Clients are (i) Shenzhen Commando Capital Management Co., Ltd. ( ଉέ̹ੰਟᅃ༟͉၍ଣ
|
||
ʮ̡ ) investing for and on behalf of nine different funds in the PRC, with the ultimate beneficial owners
|
||
holding 30% or more interest in such funds being Ding Ying ( ɕๅ), Huang Xiaolei ( රወᑜ) and Guo Hongqi
|
||
(փ), with no other persons holding 30% or more interests therein; and (ii) Beevest Capital Management
|
||
Limited, investing for and on behalf of Global Multi Alpha Fund SP, with the ultimate beneficial owner holding
|
||
30% or more interest in such fund being Zeng Shuzhen and (iii) Perseverance Asset Management L.l.p. ( ɪऎ
|
||
৷ᆇ༟ପ၍ଣΥྫΆุ (Υྫ )), investing for and on behalf of five different funds in the PRC, with no
|
||
ultimate beneficial owners holding 30% or more interest in such funds. To the best of CSICM ’s knowledge,
|
||
after making all reasonable inquiries, each of the CSICM Ultimate Clients and its ultimate beneficial owner
|
||
is a third party independent from CSICM, CLSA and the companies which are members of the same group of
|
||
companies as CLSA
|
||
|
||
|
||
--- page 27 ---
|
||
27
|
||
DISCLAIMERS
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and
|
||
Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim
|
||
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or
|
||
any part of the contents of this announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into
|
||
the United States (including its territories and possessions, any state of the United States and
|
||
the District of Columbia). This announcement does not constitute or form a part of any offer or
|
||
solicitation to purchase or subscribe for securities in the United States. The securities mentioned
|
||
herein have not been, and will not be, registered under the United States Securities Act of 1933,
|
||
as amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United
|
||
States except pursuant to an exemption from the registration requirements of the U.S. Securities
|
||
Act and in compliance with any applicable state securities laws, or outside the United States
|
||
unless in compliance with Regulation S under the U.S. Securities Act. There will be no public
|
||
offer of securities in the United States.
|
||
The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined
|
||
in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under
|
||
the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on
|
||
Regulation S under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer
|
||
to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
|
||
investors should read the Prospectus dated December 30, 2025 issued by Shenzhen Edge Medical
|
||
Co., Ltd.for detailed information about the Global Offering described below before deciding
|
||
whether or not to invest in the H Shares thereby being offered.
|
||
* Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall
|
||
Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to
|
||
terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect
|
||
upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting
|
||
Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination ” in
|
||
the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is
|
||
currently expected to be on Thursday, January 8, 2026).
|
||
|
||
|
||
--- page 28 ---
|
||
28
|
||
PUBLIC FLOAT AND FREE FLOAT
|
||
Immediately after the completion of the Global Offering, 191,842,718 H Shares, representing
|
||
approximately 49.48% of the issued share capital of our Company (before any exercise of the
|
||
Over-allotment Option) will count towards the public float. Therefore, the number of H shares held
|
||
in public hands is higher than the prescribed percentage of H Shares required to be held in public
|
||
hands of 15% under Rule 19A.13A(1) of the Listing Rules, satisfying the minimum percentage
|
||
requirement in compliance with Rule 19A.13A(1) of the Listing Rules calculated based on the
|
||
Offer Price of HK$43.24 per Offer Share.
|
||
Each of the Cornerstone Investors has agreed to a lock-up period of six months following the
|
||
Listing Date. As such, Shares held by the Cornerstone Investors upon the Listing shall not be
|
||
counted towards the free float of the Shares of the Company at the time of Listing. Based on the
|
||
final Offer Price of HK$43.24 per H Share, the Company satisfies the free float requirement under
|
||
Rule 19A.13C(1)(b) of the Listing Rules.
|
||
The Directors confirm that, immediately following completion of the Global Offering: (i) the
|
||
Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule
|
||
8.08(2) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than
|
||
50% of the H Shares held in public hands at the time of Listing, in compliance with Rules 8.08(3)
|
||
and 8.24 of the Listing Rules; (iii) no placee will, individually, be placed more than 10% of the
|
||
enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there
|
||
will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the
|
||
Global Offering.
|
||
COMMENCEMENT OF DEALINGS
|
||
The H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time)
|
||
on Thursday, January 8, 2026, provided that (i) the Global Offering has become unconditional
|
||
in all respects, and (ii) the right of termination described in the section headed “Underwriting –
|
||
Underwriting Arrangements and Expenses – Hong Kong Underwriting Agreement – Grounds for
|
||
termination ” in the Prospectus has not been exercised. Investors who trade H Shares prior to the
|
||
receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so
|
||
entirely at their own risk. Assuming that the Global Offering becomes unconditional at or before
|
||
8:00 a.m. (Hong Kong time) on Thursday, January 8, 2026, it is expected that dealings in the H
|
||
Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, January 8, 2026. The H
|
||
Shares will be traded in board lots of 100 H Shares each and the stock code of the H Shares will be
|
||
2675.
|
||
By order of the Board
|
||
Shenzhen Edge Medical Co., Ltd.
|
||
(深圳市精鋒醫療科技股份有限公司 )
|
||
Dr. Wang Jianchen
|
||
Chairman of the Board and Executive Director
|
||
Hong Kong, January 7, 2026
|
||
As of the date of this announcement, the board of directors of the Company comprises (i) Dr.
|
||
Wang Jianchen, Dr. Gao Yuanqian and Ms. Wu Mengyuan as executive directors; (ii) Mr. Sheng
|
||
Li, Mr. Chen Gang and Mr. Qiu Xiang as non-executive directors, and (iii) Mr. Yang Fan, Mr.
|
||
Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive directors.
|